NCT07259811Active, not recruiting
Vertebral Augmentation Using VCFix Spinal System in Stand-alone Configuration
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
This study will review the safety and possibility of the VCFix Spinal System. This is a proof-of-concept study and an initial review of the surgical procedure and how well the VCFix device works, to who that the VCFix is safe and works well in early testings, so that a larger safety study can be done later to help get CE approval. The VCFix Spinal System will be used in its independent setup, within its planned use for treatment of vertebral compression fracture. It's designed to be a small early study to test safety and see if the treatment idea is possible, with one group and no blinding. Two hospitals in EU will enroll in total 10 participants with a single vertebral fracture that will undergo the same surgery. The main test goals are: how successful the access creation of the vertebral body is using the VCFix Preparation kit according to the provided instructions, how successful the positioning of the VCFix implant is by using the VCFix Implantation kit according to the provided instructions, and how successful the fracture reduction by expanding the VCFix implant according to the provided instructions. The main safety goal is: number of device-/procedure-related major side effects through 30 days after the initial procedure. Participant enrollment will last around 12 months. Each participant will be followed for 2 years after the implantations. All side effects related to the spine will be documented throughout the study.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- 18 Sept 2023
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Amber Implants B.V.
- Diseases
- Osteoporosis
- NCT number
- NCT07259811
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 18 Sept 2023 to the primary completion date, 30 Sept 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Vertebral fracture prior to the incident fracture
- Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture
- Significant clinical comorbidity that the enrolling physician considers may either contraindicate surgery or interfere with long-term data collection or follow-up
- Concurrent participation in any other clinical study for which the primary outcomes are not achieved
- Patient non-ambulatory prior to fracture
- Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for \> 3 months)
- The patient is currently on anti-cancer therapy or anti-HIV therapy
- Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery
Other illness
- Pain due to any other condition that requires daily narcotic medication
- Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
- Any evidence of substance use disorder (alcohol, drugs)
Lab values
- Pre-existing conditions such as:
- Allergy to any components of the device/instruments used during the procedure or to PMMA bone cement
- Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
- Irreversible coagulopathy or bleeding disorder
- Uncontrolled diabetes (HbA1c \>8%)
- Severe cardiopulmonary deficiencies
Other
- Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
- Non-mobile fractures (i.e., fracture is not recent (\>6 weeks), bone marrow oedema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction) 2
- Fracture to the pedicle based on radiographic evaluation
- Asymptomatic vertebral fractures
- Patient clearly improving with pharmacological treatment
- Spinal cord compression or canal compromise requiring decompression
- Severe back pain due to causes other than acute fracture with NPRS score \> 5
- Pre-existing neurological deficit, radiculopathy or myelopathy
- Contraindications to MRI or radionuclide bone scan
- A life expectancy less than the study duration or undergoing palliative care
- Spondylolisthesis \>Grade 1 at target vertebral body(s)
- Local kyphotic angle \>30°
- The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
- Pregnancy or patients with child-bearing potential who do not accept taking contraception throughout the study duration
- Patients who require anterior stabilisation
Who the study is looking for
- Male or Female between 22 and 85 years of age
- One (single) vertebral fracture which meets all the following criteria:
- Type A fractures as defined by the AO spine classification (compression injuries)1
- Vertebral fracture located in the thoracic and lumbar regions of the spine
- Fracture age \<6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
- Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 70% based on radiographic evidence
- Target VB has appropriate anatomy, i.e., suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery Patient has a Numerical Pain Rating Scale (NPRS) back pain score of ≥5
- Patient has an Oswestry Disability Index (ODI) score of ≥30/100
- Patient has a BMI \<35
- Patient is mentally capable of complying with trial protocol requirements for the duration of the study
- Patient can understand the risks and benefits of participating in the study and can provide written informed consent
- Patient is available for all study visits
Age in the registry: 22 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wilhelmsburger Krankenhaus Groβ-Sand Coordinator of this site? Confirm its status | Hamburg | Germany | Unknown status |
| Krankenhaus Mechernich Coordinator of this site? Confirm its status | Mechernich | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.